LOADING

Type to search

Blueprint Medicines Publishes Inaugural Corporate Responsibility Report

ESG News ESG Reporting Lifestyle

Blueprint Medicines Publishes Inaugural Corporate Responsibility Report

— Report highlights efforts to deliver sustainable value to patients and communities, foster a diverse and empowered workforce, and operate with exceptional integrity —

Blueprint Medicines Corporation (NASDAQ: BPMC) today published its first Corporate Responsibility Report, highlighting its long-standing commitment to deliver sustainable value to patients with cancer and blood disorders, as well as the communities in which it operates. The report, which formalizes the company’s efforts to track and report environmental, social and governance (ESG) standards and initiatives, includes summaries and performance metrics that demonstrate its purpose-driven culture and socially conscious business practices.

See related article: Sherwin-Williams Issues 2021 Sustainability Report

“Since we began operations just over a decade ago, Blueprint Medicines has become a leading precision therapy company, fueled by our profound sense of mission to drive scientific innovation and deliver life-changing treatments to patients, as well as make positive impacts on the multitude of people and communities we touch along the way,” said Kate Haviland, Chief Executive Officer of Blueprint Medicines. “As we continue to grow our business, we are committed to being a force for good, and our first Corporate Responsibility Report is an important step toward this goal by providing transparency into our ongoing efforts as well as a foundation for future progress.”

The report summarizes the company’s activities across five interconnected domains including patient access and community engagement, research and development, employees and culture, environmental sustainability, and governance and integrity, and adopts accounting standards for the biotechnology and pharmaceuticals industry from the Sustainability Accounting Standards Board (SASB). The report was developed by a cross-functional corporate responsibility working group with direction from the Executive Team and oversight from the Nominating and Corporate Governance Committee of Blueprint Medicines’ Board of Directors. It is available for download at www.BlueprintMedicines.com/Our-Responsibility.

Source: PRNewswire

Tags:

Leave a Comment

Your email address will not be published. Required fields are marked *